RT Journal Article
SR Electronic
T1 Comparison Between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as Palliative First-line Chemotherapy for Adenocarcinoma of the Upper Gastrointestinal Tract
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3455
OP 3459
VO 33
IS 8
A1 ILHAN-MUTLU, AYSEGÜL
A1 PREUSSER, MATTHIAS
A1 SCHOPPMANN, SEBASTIAN F.
A1 ASARI, REZA
A1 BA-SSALAMAH, AHMED
A1 SCHWAMEIS, KATRIN
A1 PLUSCHNIG, URSULA
A1 BIRNER, PETER
A1 PÜSPÖK, ANDREAS
A1 ZACHERL, JOHANNES
A1 HEJNA, MICHAEL
YR 2013
UL http://ar.iiarjournals.org/content/33/8/3455.abstract
AB Background: The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma. In this analysis, we compare DCF and EOX regarding toxicity and efficacy. Patients and Methods: Patients received either intravenous docetaxel at 75 mg/m2, cisplatin at 75 mg/m2, both given on day 1, and 5-fluorouracil at 750 mg/m2, on days 1 to 5, or epirubicin at 50 mg/m2 i.v. on day 1, oxaliplatin at 130 mg/m2 i.v. on day 1 and capecitabine at a twice-daily dose of 1000 mg/m2 p.o. for two weeks; both regimens were repeated every three weeks. Results: Response rates for DCF and EOX were 28% and 10%, time-to-progression was 26 and 20 weeks, and overall survival were 54 and 52 weeks, respectively. Conclusion: We conclude that further investigations within comparative prospective clinical trials of these regimens are warranted.